More recently, the SARS-CoV-2 pandemic highlighted IL-6 as a key cytokine in COVID-19, where elevated IL-6 concentrations predicted the need for mechanical ventilation and were associated with hyperinflammatory states resembling CRS or HLH, raising the hypothesis that IL-6 may serve as a therapeutic target in COVID-19 analogous to its role in CRS [25,26,27,28]. The gene discussed is IL6; the disease is congenital rubella syndrome.